Lipid nanoparticles for mRNA delivery

Purpose: mRNA has therapeutic potential for vaccines, protein replacement, cancer immunotherapy, cellular reprogramming, and genome editing, but it requires safe, effective, and stable delivery systems to protect it from degradation and enable cellular uptake and mRNA release. Lipid nanoparticles have entered the clinic for mRNA delivery, most notably in COVID-19 mRNA vaccines.

Hypothesis: If mRNA is formulated into optimized lipid nanoparticles—using appropriate cationic/ionizable lipids, helper lipids, cholesterol, and PEG-lipids, with suitable administration routes and manufacturing controls—then mRNA can be protected, delivered to target cells, released into the cytoplasm, translated into therapeutic proteins, and used clinically for infectious diseases, cancer, and genetic disorders.

Aims: Review representative lipid nanoparticles used for mRNA delivery, including cationic lipids, ionizable lipids, and other lipid components. - Describe physiological barriers and administration routes for LNP-mRNA systems. - Discuss key considerations for clinical translation: GMP, stability, storage, and safety. - Highlight preclinical and clinical studies of LNP-mRNA therapeutics for infectious diseases, cancer, and genetic disorders. - Provide future perspectives and remaining challenges.

Delivery system: Platform: lipid nanoparticles (LNPs), typically containing ionizable/cationic lipid, phospholipid, cholesterol, and PEG-lipid. - Key lipids discussed: cationic lipids (DOTMA, DOTAP, DDAB, DOSPA, BHEM-Cholesterol, ePC); ionizable lipids (DLin-MC3-DMA, L319, Lipid 5, SM-102, ALC-0315, C12-200, cKK-E12, OF-02, OF-Deg-Lin, TT3, FTT5); helper lipids (DSPC, DOPE); cholesterol analogues; PEG-lipids (PEG2000-DMG, PEG2000-DSG). - Payloads: mRNA, self-amplifying RNA, circular RNA, CRISPR-Cas9 components, antigen mRNA, protein-replacement mRNA, cytokine/immunomodulator mRNA, antibody mRNA. - Administration routes: intravenous, intramuscular, intradermal, subcutaneous, intranasal, intratumoral, inhalation, and in utero. - Targeting/functionalization: antibody coating, ligand conjugation, organ-selective lipid ratios, spleen/lung targeting.

Approach: Review and synthesis of preclinical and clinical literature. Preclinical models include mice, non-human primates, and various disease models. Clinical examples include COVID-19 mRNA vaccines mRNA-1273 and BNT162b2, influenza vaccines, Zika vaccine, personalized cancer vaccines, protein replacement therapies, and CRISPR-Cas9 gene editing. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - LNP characterization: encapsulation, particle size, charge, stability. - In vivo expression, immunogenicity, and biodistribution assays. - GMP manufacturing, purification, sterilization, and storage testing. - Clinical trial endpoints: safety, tolerability, seroconversion, immune responses, tumor response, and lung function.

Key results: COVID-19 mRNA vaccines mRNA-1273 and BNT162b2 showed ~95% efficacy in phase III trials and use ionizable LNPs (SM-102 and ALC-0315, respectively). - Influenza mRNA-1440: 100 µg dose induced 78.3% HAI and 87.0% MN seroconversion for H10N8; mRNA-1851: 50 µg dose induced 96.3% HAI and 100% MN seroconversion for H7N9. - Zika vaccine mRNA-1893: 10 µg and 30 µg doses induced 94% and 100% seroconversion, respectively, and were generally well tolerated. - FixVac melanoma vaccine: >75% of patients generated immune responses against at least one tumor-associated antigen after the eighth immunization; combination with anti-PD1 gave >35% tumor regression in checkpoint inhibitor-experienced patients. - mRNA-4157 personalized cancer vaccine: monotherapy 14/16 patients remained disease-free (median follow-up 8 months); combination cohort had 50% overall response rate and median progression-free survival of 9.8 months. - mRNA-2752 intratumoral therapy: among 22 patients, six had stable disease, one had partial response with 52% tumor reduction, and five showed tumor shrinkage. - MRT5005 for cystic fibrosis: three patients at 16 mg showed maximal PPFEV1 increases of 11.1%, 13.6%, and 22.2% on day 8 post-nebulization. - mRNA-1944 anti-chikungunya antibody: single IV doses of 0.1, 0.3, and 0.6 mg/kg produced 2.0, 7.9, and 10.2 µg/mL CHKV-IgG at 24 h; half-life ~69 days. - Storage: addition of 5% sucrose or trehalose allowed maintenance of mRNA delivery efficacy for at least 3 months in liquid nitrogen.

Interpretation: The authors conclude that lipid nanoparticle-mRNA technology has demonstrated clinical potential at unprecedented speed, especially through COVID-19 vaccines. They argue that further improvements in mRNA engineering, lipid design, hybrid nanoparticles, targeting, and manufacturing will expand mRNA therapeutics for infectious diseases, cancer, and genetic disorders.

Limitations: Review article; no primary data, effect sizes, n values, doses, or controls. - Endosomal escape remains inefficient; only a small amount of LNP can escape the endosome. - PEG-lipids can induce hypersensitivity and anti-PEG antibodies, causing accelerated blood clearance. - Cationic/ionizable lipids can stimulate pro-inflammatory cytokines, reactive oxygen species, and cytotoxicity. - mRNA immunogenicity can suppress antigen expression and is undesirable for protein replacement or genome editing. - Cold-chain storage requirements increase cost and logistics burden. - Long-term safety, repeated dosing, and manufacturing scalability remain challenges.